Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: From 10-K--preferred stock (Note in bold)

"From the 10-K it would appear that the BoD have got it under control: a core focus on reducing expenditure and developing PDSG in line with revenue; written off/sold extraneous divisions with the benefit of tax loss offsets on future profits(effectively making the much maligned M&A investments cost neutral); and commenced litigation against TPL/Alliacense."

Sorry, but this is just the kind of spin that gets old. There comes a time when one must be held accountable for past failures. Justifying bad M&A decissions with the "we get to write off the losses on future profits" is not accepable when the revenue stream is not reliable. If RG was the reason, then good for them he is gone. I also believe Schrock (sp?), as much as I was excited to see him join the BoD, is in charge of M&A, then he should be shown the door as well. Just my opinion.

Good luck everyone!

Share
New Message
Please login to post a reply